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ABSTRACT
Acute myeloid leukemia (AML) is a devastating illness which carries a very poor 
prognosis, with most patients living less than 18 months. Leukemia relapse may 
occur because current therapies eliminate proliferating leukemia cells but fail to 
eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease 
after a period of latency. While we demonstrated that p53 target gene Necdin 
maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and 
response to chemotherapy are unclear. In this study, we utilized two well-established 
murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine 
the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the 
number of functional LICs and enhanced myeloid differentiation in vivo, leading to 
delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs 
expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin 
enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, 
manifested by decreased viability and enhanced apoptosis. We observed decreased 
expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin 
null leukemia cells following chemotherapy treatment, indicating that p53-dependent 
apoptotic pathways may be activated in the absence of Necdin. In addition, we found 
that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem 
and progenitor cells in transplantation assays. However, Necdin-deficiency did not 
affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. 
Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response 
in a context-dependent manner. Our findings suggest that pharmacological inhibition 
of Necdin may hold potential as a novel therapy for leukemia patients with MLL 
translocations.
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INTRODUCTION
Acute myeloid leukemia (AML) is the most 
common acute leukemia in adults. It usually occurs 
around age 60 with no identifiable cause and it carries a 
very poor prognosis, with most patients living less than 
18 months [1]. Leukemia can be viewed as a malignancy 
initiated in a hematopoietic stem cell (HSC) or primitive 
progenitor cell that has maintained or acquired the 
capacity for self-renewal and is blocked in its ability to 
differentiate by the accumulation of a series of mutations 
and/or epigenetic changes [2–4]. The initial treatment of 
leukemia is designed to achieve a complete remission, 
meaning that the leukemic cells are not detectable in the 
bone marrow and normal blood formation has recovered. 
Leukemia relapse may occur because current therapies 
eliminate proliferating cells (that constitute the bulk 
of the disease) but fail to eradicate dormant leukemia-
initiating cells (LICs) that can reinitiate the disease after 
a period of latency (the duration of remission) [1–2]. 
LICs, and in particular those that are in a dormant state, 
are resistant to chemotherapy or targeted therapies [5–7]. 
The development of new therapeutic approaches that can 
target LICs will have a profound impact on our ability to 
eradicate leukemia [8–10]. Unfortunately, little progress 
has been made in treating AML over the past 4 decades 
[1]. Clearly, new treatment strategies are urgently needed.
AML is characterized by recurrent chromosomal 
translocations, which generally target transcriptional 
regulatory genes, generating fusion proteins like MLL-AF9 
and AML1-ETO [11–12]. MLL is a histone methyltransferase 
and MLL-AF9 is a 170 kDa fusion protein, generated by 
the t(9;11) [11]. MLL-AF9 is a frequently occurring MLL 
fusion oncogene typically associated with the FAB-M4 or 
M5 subtypes of human AML [11]. MLL associated leukemia 
accounts for the majority of infant leukemia, approximately 
10% of adult de novo leukemia and approximately 33% of 
therapy related acute leukemia with a balanced chromosome 
translocation [11]. The presence of an MLL rearrangement 
generally confers a poor prognosis [1, 11]. MLL-AF9 is 
capable of transforming hematopoietic progenitor cells 
(HPCs) and HSCs, thus it can impart self-renewal to a non-
self-renewing cell [13].
The t(8;21)(q22;q22) translocation is one of the 
most common genetic abnormalities in acute myeloid 
leukemia (AML), identified in 15% of all cases of AML, 
including 40–50% of FAB M2 subtype and rare cases of 
M0, M1 and M4 subtypes [12]. AML1-ETO is insufficient 
to cause acute leukemia by itself in human or mouse cells 
[14–15]. However, a truncated form of the AML1-ETO 
fusion protein (called AML1-ETO exon 9a) is sufficient 
to cause leukemia in mice, with a rather short latency 
[16–17]. AML1-ETO+ AML remains a significant clinical 
problem, with 30% of patients relapsing and long-term 
survival rates ranging between 30 and 60%, indicating the 
need for improved therapeutic approaches [18–19].
We are turning our attention to leukemia-initiating 
cells (LICs) to generate additional knowledge in order to 
develop therapeutic strategies that can eliminate the largely 
quiescent LICs and improve leukemia treatment. We have 
defined a critical role for p53 in regulating hematopoietic 
stem cell quiescence, and identified Necdin as a p53 target 
gene whose promoter binds and is transactivated by p53 
[20–21]. Necdin is a growth suppressing protein first 
identified in post-mitotic neurons [22–23] and the gene 
encoding Necdin is one of several genes that are deleted 
in individuals with Prader-Willi syndrome [24]. Like the 
retinoblastoma protein, Necdin interacts with multiple cell 
cycle promoting proteins, such as simian virus 40 large 
T antigen, adenovirus E1A and the transcription factor 
E2F1 [25–27]. Necdin is highly expressed in long-term 
hematopoietic stem cells, and we have demonstrated that 
Necdin functions as a rheostat controlling HSC quiescence 
[21, 28]. Necdin null HSCs are more cycling and more 
easily exhausted, suggesting that Necdin is required for 
HSC maintenance [21].
Given that Necdin is essential for HSC quiescence 
and some patients with Prader-Willi syndrome develop 
AML [20-21, 29], we hypothesized that Necdin deficiency 
will stimulate quiescent LICs to enter the cell cycle and 
sensitize them to chemotherapy and improve leukemia 
treatment. To test this, we utilized two well-established 
mouse models of human AML, including MLL-AF9 and 
AML1-ETO9a, to determine the role of Necdin in LIC 
proliferation and chemotherapy response [13, 16]. We 
discovered that loss of Necdin decreased the quiescence of 
MLL-AF9+ LICs and sensitized leukemia cells expressing 
MLL-AF9 to chemotherapy treatment.
RESULTS
Necdin deficiency enhances the proliferation of 
hematopoietic progenitor cells expressing  
MLL-AF9
We utilized a mouse model of human AML induced 
by the MLL-AF9 oncogene to determine the role of 
Necdin in the initiation and progression of AML [13]. We 
infected wild type and Necdin null fetal liver cells, which 
contain hematopoietic stem and progenitor cells (HSPCs), 
with retroviruses expressing GFP or MLL-AF9. Robust 
expression of the GFP was seen 72h post-infection (Figure 
1A). We cultured transduced cells (GFP+) in serum free 
medium in the presence of cytokines for seven days and 
then examined the frequency of HSPCs. We found that 
loss of Necdin increased the frequency of Kit+CD11b-Gr1- 
cells and decreased the frequency of Kit+CD11b+Gr1+ cells 
(Figure 1B and 1C). Given that leukemia-initiating cells 
or leukemia stem cells (LSCs) in murine model of MLL-
AF9+ AML are Kit+CD11b+Gr1+ cells [13, 30], our finding 
suggests that Necdin-deficiency may decrease the number 
of LICs in MLL-AF9-induced leukemia.
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In the serial replating assay, wild-type fetal liver 
cells cannot be replated more than three times (Figure 
1D). While Necdin null HSPCs show decreased colony 
formation in week 1, the replating potentials of Necdin null 
cells and wild-type cells are comparable (Figure 1D). We 
then performed serial replating assays using wild type and 
Necdin null fetal liver cells expressing MLL-AF9. While 
Necdin null cells show decreased colony formation in 
week one compared to wild-type cells, they show enhanced 
colony formation potential compared to wild-type cells in 
following weeks (Figure 1E). To determine the effect of 
Necdin deficiency on HSPC proliferation, we cultured wild 
type and Necdin null fetal liver cells expressing MLL-AF9 
in medium containing hematopoietic cytokines. 48 and 72 
hours later, we counted cell number using flow cytometry 
and found that expression of MLL-AF9 enhanced the 
proliferation of Necdin null HSPCs compared to wild type 
HSPCs (Figures 1F and 1G).
Necdin deficiency delays the progression of 
leukemia-induced by MLL-AF9
To determine the role of Necdin in MLL-AF9-
induced leukemia, we transplanted 100,000 wild type or 
Necdin null HSPCs expressing MLL-AF9 cells (CD45.2+ 
GFP+) into lethally irradiated recipient mice (B6.SJL 
mice, CD45.1+) together with 100,000 normal competitor 
cells (CD45.1+). We monitored leukemia progression 
in recipient mice by checking GFP+ leukemic cells in 
the peripheral blood every 4 weeks. We observed rapid 
expansion of GFP+ leukemia cells in recipient mice 
repopulated with both wild -type and Necdin null HSPCs 
expressing MLL-AF9 at 4 weeks following transplantation 
(Figures 2A and 2B). We observed several population of 
Gr1+ cells with different GFP intensity in the peripheral 
blood of recipient mice repopulated with Necdin null 
HSPCs expressing MLL-AF9 (Figure 2A), suggesting that 
Necdin may affect the differentiation of LICs expressing 
MLL-AF9.
In the bone marrow transduction and transplantation 
model of MLL-AF9, all recipient mice developed AML, 
with a median latency of 84.5 days [13]. We utilized 
fetal liver cells and obtained similar results. There is no 
apparent effect of Necdin deficiency on the survival of 
recipient mice and all recipient mice transplanted with 
wild type or Necdin null mice died 11 weeks following 
transplantation (Figure 2C), suggesting that Necdin 
is dispensable for the initiation and/or progression of 
leukemia induced by MLL-AF9 in primary transplantation 
assays. We transplanted 3 x 106 GFP+ MLL-AF9+ bone 
marrow cells (CD45.2+) isolated from the primary 
recipient mice into lethally irradiated recipient mice (B6.
SJL, CD45.1+). We monitored leukemia development in 
recipient mice. While it takes 10 weeks for MLL-AF9 to 
induce leukemia in the primary recipient mice (Figure 2C), 
it only takes 3 weeks for these leukemia cells to develop 
leukemia in secondary recipients (Figure 2D). Importantly, 
we found that Necdin-deficiency significantly delayed 
leukemia onset (Figure 2D), suggesting that Necdin is 
important for the progression of leukemia induced by 
MLL-AF9 in transplantation assays.
Given that Necdin maintains HSC quiescence [20–
21] and GMPs (Lin-Sca1-IL7R-Kit+FcγRII/IIIhighCD34high) 
are leukemia-initiating cells (LICs) in MLL-AF9 induced 
leukemia [13], we examined the impact of Necdin 
deficiency on the quiescent state of GMPs using Ki67 and 
DAPI staining. We found that loss of Necdin significantly 
decreased the number of quiescent GMPs (Ki67-) in the 
bone marrow of leukemia mice (Figure 2E), suggesting 
that Necdin maintains the quiescence of leukemia-
initiating cells expressing MLL-AF9.
To further investigate the mechanisms by which 
Necdin deficiency delays leukemia progression, we 
examined the frequency of Kit+ cells, GMPs, and 
Gr1+CD11b+ cells in the bone marrow of leukemia mice. 
We found that loss of Necdin decreased the frequency 
of Kit+ cells and GMPs in the bone marrow (Figure 2F), 
suggesting that the number of LICs was decreased in the 
bone marrow of leukemia mice in the absence of Necdin. 
Further, we observed decreased number of mature myeloid 
cells (Gr1+CD11b+) in the bone marrow of leukemia 
mice repopulated with Necdin null cells (Figure 2G), 
indicating that Necdin deficiency promotes myeloid 
differentiation. To determine the functional impact of 
Necdin deficiency on LICs, we performed serial replating 
assays. While Necdin null LICs (GMPs) generated more 
colonies than wild type cells in Week 1, these cells 
show decreased colony formation capability compared 
to wild type leukemia cells in following weeks (Figure 
2H), demonstrating that Necdin deficiency impairs LIC 
function in vitro.
Loss of Necdin sensitizes leukemia cells 
expressing MLL-AF9 to chemotherapy
Given that loss of Necdin decreased the quiescence 
of GMPs expressing MLL-AF9 (Figure 2E), we predicted 
that Necdin null leukemia cells expressing MLL-AF9 
would be sensitive to chemotherapy. That was indeed 
the case. We treated wild type and Necdin null leukemia 
cells expressing MLL-AF9 with DMSO or different 
concentrations of chemotherapy drug cytarabine (AraC) 
and monitored cell viability by cell counting. While 
24 hour AraC treatment did not affect the viability of 
leukemia cells expressing MLL-AF9 (Figure 3A), we 
found that Necdin null leukemia cells expressing MLL-
AF9 were sensitive to extended AraC treatment (48 hour) 
in a dosage-dependent manner, manifested by decreased 
viability (Figure 3B). While the LC50 for AraC on wild 
type leukemia cells is 0.16 μM, the LC50 for AraC on 
Necdin null leukemia cells expressing MLL-AF9 is 0.09 
μM. We then examined the impact of AraC treatment on 
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Figure 1: Necdin deficiency enhances the proliferation of hematopoietic progenitor cells expressing MLL-AF9. (A) 
Fetal liver cells isolated from wild-type (WT) or Necdin knock-out (KO) mice were transduced with retroviruses expressing GFP (MIGR1) 
or MLL-AF9. Representative flow cytometry plots show the frequency of transduced cells (GFP+) 72 hours following transduction. (B) 
Transduced wild type and Necdin null fetal liver cells (GFP+) were cultured in serum free medium in the presence of cytokines for seven 
days. The frequency of hematopoietic stem and progenitor cells was determined by flow cytometry analysis. Representative flow cytometry 
plots show the frequency of Kit+CD11b-Gr1- and Kit+CD11b+Gr1+ cells at 7 days in liquid culture. (C) The frequency of Kit+CD11b-
Gr1- and Kit+CD11b+Gr1+ cells in the liquid culture (**p<0.01, ***p<0.001, n=2). (D) Serial replating studies. CFUs were quantified by 
methylcellulose culture using WT and Necdin null fetal liver cells. The methylcellulose cultures were serially replated, weekly, for 4 weeks. 
Mean values (± SD) were shown (**p<0.01, n=3). (E) Necdin null fetal liver cells expressing MLL-AF9 show enhanced replating potential 
compared to WT cells (*p<0.05, **p<0.01, n=3). (F) and (G) Liquid culture of WT and Necdin null fetal liver cells expressing MLL-AF9. 
48 (F) and 72 (G) hours later, cell proliferation was determined by cell counting. Cell growth was presented relative to the number of input 
cells in each group, set as 1 (*p<0.05, **p<0.01, n=3).
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leukemia cell survival. The number of total apoptotic cells 
was comparable between two groups following 24 hour 
AraC treatment (Figure 3C). While loss of Necdin did 
not affect the early apoptosis of leukemia cells expressing 
MLL-AF9 following 48 hour AraC treatment (Figure 3D), 
the number of late apoptotic cells (Annexin V+/PI+) was 
significantly increased in Necdin null group compared 
with wild type group following high concentration of 
AraC (0.5 μM) treatment (Figure 3E). We then performed 
cell cycle analysis of leukemia cells treated with DMSO 
Figure 2: Necdin deficiency delays the progression of leukemia-induced by MLL-AF9. (A) Primary transplantation of fetal 
liver cells expressing MLL-AF9. Representative flow cytometry plots show the frequency of GFP+Gr1+ cells in the peripheral blood of 
recipient mice 4 weeks following transplantation. (B) The frequency of donor-derived cells (CD45.2+GFP+) in the peripheral blood (PB) 
of recipient mice was determined by flow cytometry analysis (p=0.2, n=5). (C) Survival curve of animals transplanted with wild type 
or Necdin null fetal liver cells expressing MLL-AF9 (p=0.2, n=5). (D) Bone marrow cells isolated from primary recipient mice were 
transplanted into lethally irradiated recipient mice. Survival curve of recipient mice transplanted with WT or Necdin null leukemia cells 
expressing MLL-AF9 (*p<0.05, n=7). (E) The quiescence of GMPs in the BM of leukemia mice were determined by Ki67 and DAPI 
staining. Quiescent cells are defined as Ki67- cells (*p<0.05, n=3). (F) The frequency of Kit+ cells and GMPs in the BM of leukemia mice 
was determined by flow cytometry analysis (*p<0.05, **p<0.01, n=5). (G) The frequency of myeloid cells (Gr1+CD11b+) in the BM of 
leukemia mice was determined by flow cytometry analysis (*p<0.05, n=5). (H) Necdin null GMPs expressing MLL-AF9 show decreased 
replating potential compared to wild type leukemia cells (***p<0.001, n=3).
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or AraC (0.2 μM). While AraC treatment did not affect the 
cell cycle status of wild type leukemia cells expressing 
MLL-AF9, AraC treatment increased the number of 
Necdin null leukemia cells in the G0/G1 phase of the cell 
cycle and decreased the number of Necdin null leukemia 
cells in the S phase of the cell cycle (Figure 3F).
To understand the molecular basis of enhanced 
apoptosis and cell cycle arrest seen in the Necdin null 
leukemia cells following AraC treatment, we examined 
the expression of genes that regulate apoptosis and cell 
cycle, including Bcl2, Bax and p53, in leukemia cells 
treated with DMSO or AraC. We observed decreased 
levels of Bcl2 and increased levels of p53 and its target 
gene Bax in Necdin null leukemia cells compared to wild 
type leukemia cells following AraC treatment (Figure 
3G). While Bcl2 inhibits apoptosis, Bax promotes p53-
dependent apoptosis following genotoxic stress [31–32]. 
These findings suggest that Necdin deficiency may 
activate the p53-dependent apoptotic pathways in MLL-
AF9+ leukemia cells following AraC treatment.
Necdin deficiency decreases the proliferation of 
hematopoietic progenitor cells expressing AML1-
ETO9a
In addition to MLL-AF9-induced leukemia, we also 
utilized a mouse model of human AML induced by the 
AML-ETO9a oncogene to determine the role of Necdin in 
leuekmia initiation and progression [16]. We infected wild 
type and Necdin null HSPCs with retroviruses expressing 
GFP or AML1-ETO9a. Robust expression of GFP was 
seen 72h post-infection (Figure 4A). We then cultured 
transduced cells (GFP+) in serum free medium in the 
presence of cytokines for seven days and then examined 
the frequency of HSPCs. We found comparable numbers 
of Kit+CD11b-Gr1- and Kit+CD11b+Gr1+ cells in both 
wild type and Necdin null cell cultures (Figures 4B and 
4C). We performed serial replating assays using wild type 
and Necdin null HSPCs expressing AML-ETO9a. While 
Necdin null HSPCs show decreased colony formation in 
week one compared to that of the WT cells, these cells 
show enhanced colony formation than that of the wild type 
cells by week 4 (Figure 4D). We then examine the effect 
of Necdin deficiency on HSPC proliferation and found 
that Necdin null HSPCs expressing AML1-ETO9a show 
decreased proliferation compared to wild type HSPCs 
(Figures 4E and 4F), indicating that Necdin is important 
for the proliferation of HSPCs expressing AML-ETO9a.
Necdin deficiency decreases the repopulating 
potential of hematopoietic stem and progenitor 
cells expressing AML1-ETO9a
To determine the role of Necdin in AML-ETO9a 
-induced leukemia, we transplanted 100,000 wild 
type or Necdin null HSPCs expressing AML-ETO9a 
(CD45.2+GFP+) into lethally irradiated recipient mice 
(B6.SJL mice, CD45.1+) together with 100,000 normal 
competitor cells (CD45.1+). In primary transplantation, we 
observed no difference in the frequency of donor-derived 
GFP+ cells in mice repopulated with wild type or Necdin 
null HSPCs expressing AML-ETO9a at 8 weeks following 
transplantation (Figure 5A). There is no apparent effect 
of Necdin deficiency on the survival of recipient mice as 
most recipient mice transplanted with wild type or Necdin 
null mice are still alive 14 weeks following transplantation 
(Figure 5B), suggesting the Necdin may be dispensable for 
AML1-ETO9a-mediated leukemia initiation.
To determine the impact of Necdin deficiency 
on the repopulating potential of hematopoietic stem 
and progenitor cells expressing AML1-ETO9a, we 
sacrificed the primary recipient mice 16 weeks following 
transplantation and harvested GFP+ bone marrow cells 
for secondary transplantation. We performed Limiting-
dilution transplantation assays by transplanting 3 x105 
or 3 x106 AML1-ETO+ bone marrow cells (CD45.2+ 
GFP+) isolated from the primary recipient mice into 
lethally irradiated recipient mice (B6.SJL, CD45.1). 
We monitored engraftment of GFP+ hematopoietic cells 
in peripheral blood by flow cytometry every 4 weeks 
after transplantation. We found that Necdin null bone 
marrow cells show decreased engraftment using both 
concentrations of donor cells 16 weeks post transplantation 
(Figures 5C and 5D), suggesting that loss of Necdin 
decreases the repopulating potential of hematopoietic stem 
and progenitor cells expressing AML1-ETO9a.
To determine the impact of Necdin deficiency 
on hematopoietic stem and progenitor cells in vivo, we 
analyzed the bone marrow of secondary recipient mice 
repopulated with wild type or Necdin null bone marrow 
cells expressing AML1-ETO9a. We observed comparable 
number of donor-derived (CD45.2+GFP+) myeloid cells 
(CD11b+Gr1+), B cells (B220+), and T cells (CD3+) in the 
bone marrow of recipient mice from both the wild type and 
the Necdin null groups (Figure 5E), indicating that Necdin 
deficiency does not affect terminal differentiation of 
HSPCs expressing AML1-ETO9a. In addition, we found 
comparable numbers of donor-derived (CD45.2+GFP+) 
hematopoietic progenitor cells (Lin-Sca1-Kit+ and Lin-
Sca1+Kit+) in the bone marrow of recipient mice from both 
groups, suggesting that Necdin deficiency does not alter 
the frequency HSPCs expressing AML1-ETO9a in vivo 
(Figure 5F).
The impact of AraC treatment on hematopoietic 
cells expressing AML1-ETO9a
Given that loss of Necdin decreases the proliferation 
of hematopoietic progenitor cells expressing AML1-
ETO9a (Figure 4E and 4F), we predicted that Necdin-
deficient hematopoietic cells expressing AML1-ETO9a 
would not be sensitive to chemotherapy. We isolated 
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Figure 3: Necdin null leukemia cells expressing MLL-AF9 are sensitive to chemotherapy treatment. (A) and (B) WT and 
Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations of chemotherapy drug cytarabine 
(AraC). 24 (A) and 48 (B) hours after AraC treatment, the viability of treated leukemia cells was measured by cell counting (*p<0.05, 
**p<0.01, n=3). (C) WT and Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations of 
AraC. 24 hours after AraC treatment, the frequency of total apoptotic cells (Annexin V+) was determined by flow cytometry analysis 
(*p<0.05, n=3). (D) and (E) WT and Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations 
of AraC. 48 hours after AraC treatment, the frequency of early apoptotic cells (Annexin V+PI-) and late apoptotic cells (Annexin V+PI+) was 
determined by flow cytometry analysis (***p<0.001, n=3). (F) Wild type and Necdin null leukemia cells were treated with DMSO or AraC 
(0.2 μM). 24 hours later, cell cycle status of leukemia cells was determined by flow cytometry analysis (*p<0.05, ***p<0.001, n=3). (G) Wild 
type and Necdin null leukemia cells were treated with DMSO or AraC. 6 hours later, the expression of Bcl2, Bax, and p53 in leukemia cells 
was determined by quantitative real-time PCR analysis (**p<0.01, ***p<0.001, n=3).
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Figure 4: Necdin deficiency decreases the proliferation of hematopoietic progenitor cells expressing AML1-ETO9a. (A) 
Fetal liver cells isolated from wild-type (WT) or Necdin knock-out (KO) mice were transduced with retroviruses expressing GFP (MIGR1) 
or AML1-ETO9a. Representative flow cytometry plots show the frequency of transduced cells (GFP+) 72 hours following transduction. (B) 
Transduced wild type and Necdin null fetal liver cells (GFP+) were cultured in serum free medium in the presence of cytokines for seven 
days. The frequency of hematopoietic stem and progenitor cells was determined by flow cytometry analysis. Representative flow cytometry 
plots show the frequency of Kit+CD11b-Gr1- and Kit+CD11b+Gr1+ cells at 7 days in liquid culture. (C) The frequency of Kit+CD11b-Gr1- 
and Kit+CD11b+Gr1+ cells in the liquid culture (p<0.2, n=2). (D) Necdin null fetal liver cells expressing AML1-ETO9a show enhanced 
replating potential compared to WT cells (*p<0.05, **p<0.01, n=3). (E) Liquid culture of WT and Necdin null fetal liver cells expressing 
AML1-ETO9a. Cell proliferation at 48 hours was determined by cell counting. Cell growth was presented relative to the number of input 
cells in each group, set as 1 (**p<0.01, n=3). (F) Liquid culture of WT and Necdin null fetal liver cells expressing AML1-ETO9a. Cell 
proliferation at 72 hours was determined by cell counting. Cell growth was presented relative to the number of input cells in each group, 
set as 1 (**p<0.01, n=3).
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Figure 5: Necdin deficiency decreases the repopulating potential of hematopoietic stem and progenitor cells expressing 
AML1-ETO9a. (A) Primary transplantation of fetal liver cells expressing AML1-ETO9a. The frequency of donor-derived cells 
(CD45.2+GFP+) in the peripheral blood (PB) of recipient mice at 8 weeks following transplantation was determined by flow cytometry 
analysis (p=0.2, n=5-6). (B) Survival curve of animals transplanted with WT or Necdin null fetal liver cells expressing AML1-ETO9a 
(P=0.2, n=5-6). (C) and (D) Secondary transplantation assays using 3 x 105 (C) or 3 x106 (D) bone marrow cells from mice repopulated 
with WT or Necdin null fetal liver cell expressing AML1-ETO9a. The frequency of donor-derived cells (CD45.2+GFP+) in peripheral blood 
was measured by flow cytometry analysis every four weeks for 16 weeks. (*p<0.05, **p<0.01, n=5). (E) The frequency of donor-derived 
(CD45.2+GFP+) myeloid cells (CD11b+Gr1+), B cells (B220+), and T cells (CD3+) in the bone marrow of secondary recipient mice at 16 
weeks following transplantation was determined by flow cytometry analysis. (F) The frequency of donor-derived (CD45.2+GFP+) Lin-Sca1-
Kit+ and Lin-Sca1+Kit+ cells in the bone marrow of secondary recipient mice at 16 weeks following transplantation was determined by flow 
cytometry analysis.
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wild type and Necdin null hematopoietic cells from the 
secondary recipient mice repopulated with hematopoietic 
cells expressing AML1-ETO9a. We treated wild type and 
Necdin null cells with DMSO or different concentrations 
of chemotherapy drug cytarabine (AraC) and monitored 
cell viability by cell counting. We found that the viability 
of wild type and Necdin null hematopoietic cells 
expressing AML1-ETO9a were comparable following 
AraC treatment (Figures 6A, 6B and 6C). The LC50 for 
AraC on wild type cells is 0.15 μM and the LC50 for AraC 
on Necdin-deficient cells expressing AML1-ETO9a is 
0.14 μM. We then examined the impact of AraC treatment 
on the survival of hematopoietic cells expressing AML1-
ETO9a. While loss of Necdin did not affect the number of 
early apoptotic (Annexin V+/PI-) leukemia cells expressing 
AML1-ETO9a (Figure 6D), the number of late apoptotic 
cells (Annexin V+/PI+) was significantly increased in 
Necdin null group compared with wild type group 
following high concentration of AraC treatment (Figure 
6E). We also examined the apoptosis of hematopoietic 
cells 72 hours after AraC treatment. Although the number 
of early apoptotic cells was comparable in both groups 
(Figure 6F), the number of late apoptotic cells was 
decreased in the Necdin null group compared to wild type 
group (Figure 6G).
DISCUSSION
Many cancers seem to depend on a small population 
of ‘cancer stem cells’ for their continued growth and 
propagation [2]. The leukemia-initiating cell (LIC) 
or leukemia stem cell (LSC) was the first such cell to 
be described [2–3]. Leukemia-initiating cells (LICs), 
particularly those that are in a quiescent state, are resistant 
to chemotherapy or targeted therapies [5–7]. The LIC 
is likely to be the most crucial target in the treatment of 
leukemia, and a thorough understanding of its biology - 
particularly how the LIC differs from the HSC - might 
allow it to be selectively targeted, improving therapeutic 
outcome [2, 8]. However, the critical regulators of LIC 
quiescence are largely unknown [9–10]. Thus, deciphering 
the molecular mechanisms controlling LIC quiescence is 
essential for developing therapeutic strategies that can 
eliminate quiescent LICs.
Quiescence (G0) is a physiological state occupied 
by “resting” cells that have exited the cell cycle [9]. It was 
generally thought that the HSC pool turn over every few 
weeks [33–34]. However, recent findings suggest that there 
are dormant HSCs and activated HSCs in laboratory animals 
[35]. Dormant HSCs are efficiently activated in response to 
bone marrow injury or G-CSF stimulation. However, once 
the steady state is reestablished, the activated HSCs return 
to dormancy, suggesting that HSCs reversibly switch from 
dormancy to self-renewal during homeostasis and repair 
[35]. Both HSC-intrinsic regulators and bone marrow 
niche factors contribute to HSC quiescence [9]. Cell cycle 
regulators, such as PTEN, Rb, PML, and MEF, regulate 
hematopoietic stem cell quiescence [36–40]. Stem cell 
niche signals, such as Angiopoietin/Tie2 signaling, promote 
HSC quiescence [41].
We demonstrated that p53 plays a critical role in 
regulating HSC quiescence and identified Necdin as an 
important p53 target gene in HSCs [20]. To determine 
the role of Necdin in hematopoiesis, we analyzed the 
hematopoietic compartment of a strain of Necdin-null 
mice that die perinatally and have features resembling 
those seen in the human Prader-Willi Syndrome [42]. 
While Necdin functions like p53 to maintain HSC 
quiescence during steady state, Necdin opposes p53-
dependent apoptosis under conditions of genotoxic stress 
[21]. Despite being a p53 target, Necdin appears to both 
mimic and antagonize p53 function in hematopoietic stem 
and progenitor cells [20–21]. Recently, down regulation 
of p53 target genes, including Necdin and Gfi-1, in 
hematopoietic stem and progenitor cells, has been shown 
to promote ENU-induced leukemogenesis [43]. While 
some patients with Prader-Willi Syndrome develop AML 
[29], the role of Necdin in leukemogenesis is largely 
unknown. We utilized two well-established murine models 
of human AML induced by MLL-AF9 and AML1-ETO9a 
to determine the role of Necdin in leukemia development 
and discovered that Necdin controls leukemia-initiating 
cell quiescence and chemotherapy response in a context-
dependent manner.
Murine fetal liver mainly consists of hematopoietic 
stem and progenitor cells that are highly proliferative 
[44]. To determine the impact of Necdin on hematopoietic 
progenitor cell proliferation, we introduced oncogenic 
fusion proteins, including MLL-AF9 and AML1-ETO9a, 
into wild type and Necdin null fetal liver cells and 
performed proliferation assays. While loss of Necdin 
enhanced the proliferation of fetal liver cells expressing 
MLL-AF9 (Figures 1F and 1G), Necdin deficiency 
decreased the proliferation of fetal liver cells expressing 
AML1-ETO9a (Figures 4E and 4F). Thus, Necdin appears 
to play distinct roles in regulating the proliferation of 
hematopoietic progenitor cells expressing different 
oncogenic fusion proteins. The leukemia-initiating cells 
in MLL-AF9-induced leukemia are GMPs [13]. We found 
that Necdin null GMPs expressing MLL-AF9 were less 
quiescent than wild-type GMPs (Figure 2E), suggesting 
that Necdin maintains the quiescence of LICs expressing 
MLL-AF9. Whether Necdin contributes to the quiescence 
of LICs expressing AML1-ETO9a is not known. 
Based upon the effect of Necdin deficiency on normal 
hematopoietic progenitor cells expressing AML1-ETO9a 
(Figures 4E and 4F), we predict that loss of Necdin may 
enhance the quiescence of AML1-ETO9a+ LICs.
In the bone marrow transduction and transplantation 
model of MLL-AF9, all recipient mice developed AML, 
with a median latency of 84.5 days [13]. To determine 
the role of Necdin in MLL-AF9-induced leukemia, we 
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Figure 6: The impact of AraC treatment on hematopoietic cells expressing AML1-ETO9a. (A), (B), and (C) WT and Necdin 
null hematopoietic cells expressing AML1-ETO9a were treated with DMSO or different concentrations of chemotherapy drug cytarabine 
(AraC). 24 (A), 48 (B), and 72 (C) hours after AraC treatment, the viability of treated hematopoietic cells was measured by cell counting 
(n=3). (D) and (E) WT and Necdin null hematopoietic cells expressing AML1-ETO9a were treated with DMSO or different concentrations 
of AraC. 48 hours after AraC treatment, the frequency of early apoptotic cells (Annexin V+PI-) and late apoptotic cells (Annexin V+PI+) 
was determined by flow cytometry analysis (*p<0.05, **p<0.01, ***p<0.001, n=3). (F) and (G) WT and Necdin null hematopoietic cells 
expressing AML1-ETO9a were treated with DMSO or different concentrations of AraC. 72 hours after AraC treatment, the frequency of 
early apoptotic cells (Annexin V+PI-) and late apoptotic cells (Annexin V+PI+) was determined by flow cytometry analysis (*p<0.05, n=3).
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introduced MLL-AF9 into wild type and Necdin null 
fetal livers cells and performed transplantation assays. In 
primary transplantation assays, the survival rate between 
wild type and Necdin null groups was comparable 
(Figure 2C); However, Necdin deficiency significantly 
delayed the development of leukemia induced by MLL-
AF9 in secondary transplantation assays (Figure 2D). 
These findings suggest that Necdin may be important 
for the progression but not the initiation of leukemia 
induced by MLL-AF9. To understand the mechanisms 
by which Necdin deficiency delays leukemia onset, we 
characterized the behavior of GMPs in the bone marrow 
of the secondary recipient mice. We found that loss 
of Necdin decreased the number of GMPs in the bone 
marrow of recipient mice (Figure 2F). Further, Necdin 
null GMPs show decreased replating capability compared 
to wild-type GMPs (Figure 2H). These findings indicate 
that Necdin deficiency decreases both the number and 
the function of GMPs expressing MLL-AF9. In addition, 
we found increased number of myeloid cells in the bone 
marrow of recipient mice repopulated with Necdin null 
bone marrow cells compared to that of the wild-type cells 
(Figure 2G). Thus, the delayed leukemia development 
seen in the recipient mice repopulated with Necdin null 
bone marrow cells expressing MLL-AF9 may be due to 
decreased number of GMPs as well as enhanced myeloid 
differentiation.
While AML1-ETO is insufficient to cause acute 
leukemia by itself in human or mouse cells [14–15], 
AML1-ETO9a fusion protein is sufficient to cause 
leukemia in mice [16–17]. To determine the role of Necdin 
in AML1-ETO9a-induced leukemia, we introduced 
AML1-ETO9a into wild type and Necdin null fetal livers 
cells and performed transplantation assays. Sixteen weeks 
following primary transplantation assays, all recipient 
mice were still alive (Figure 4B). Given that hematopoietic 
progenitor cells expressing AML1-ETO9a show enhanced 
replating potential in vitro (Figure 4D), we predicted that 
loss of Necdin would increase the repopulating potential 
of bone marrow cells expressing AML1-ETO9a in vivo. 
To test this, we isolated bone marrow cells from primary 
recipient mice repopulated with wild type and Necdin null 
fetal liver cells and performed secondary transplantation 
assays with limiting dilution of donor bone marrow cells. 
Surprisingly, loss of Necdin decreased the number of 
donor-derived cells in the peripheral blood of secondary 
recipient mice 16 weeks post transplantation (Figures 
5C and 5D), suggesting that Necdin deficiency may 
decrease the repopulating potential of AML1-ETO9a+ 
hematopoietic stem and progenitor cells in transplantation 
assays. We only monitored the survival of secondary 
recipient mice for 16 weeks and all mice were alive at 
the time of sacrifice. Given that Necdin deficiency did not 
affect the number of hematopoietic stem and progenitor 
cells and their differentiation in the bone marrow (Figures 
5E and 5F), we predict that the survival rate would be 
comparable between wild type and Necdin null groups in 
secondary transplantation.
Despite advances in the treatment of acute myeloid 
leukemia (AML), relapse and drug resistance frequently 
occur [1]. As Necdin null HSCs are less quiescent than 
wild-type HSCs and wild type mice repopulated with 
Necdin null HSCs show enhanced sensitivity to weekly 
5-FU treatments or sub-lethal doses of irradiation [21], 
targeting Necdin may provide a therapeutic approach to 
eliminating quiescent leukemia-initiating cells. Given that 
quiescent LICs are resistant to chemotherapy treatment 
[5–9], we predicted that decreased GMP quiescence would 
sensitize Necdin-deficient leukemia cells expressing 
MLL-AF9 to AraC treatment. Indeed, we found that 
Necdin deficiency enhanced the response of leukemia 
cells expressing MLL-AF9 to chemotherapy treatment, 
manifested by decreased viability and enhanced apoptosis 
(Figures 3B and 3E). To understand the mechanisms by 
which Necdin controls chemo-sensitivity, we examined 
the expression of p53 and apoptosis related genes in 
leukemia cells treated with DMSO or AraC. We found 
that the mRNA levels of p53 and its target gene Bax were 
increased in Necdin null leukemia cells expressing MLL-
AF9 compared to wild-type leukemia cells (Figure 3G). 
However, the expression of apoptosis regulatory gene Bcl2 
was decreased in Necdin null leukemia cells compared to 
wild-type leukemia cells (Figure 3G). Necdin physically 
interacts with p53 and suppresses p53-dependent apoptosis 
in neurons and hematopoietic cells [21, 25, and 45]. These 
data suggest that p53-dependent apoptotic pathways may 
be activated in Necdin null leukemia cells expressing 
MLL-AF9 following AraC treatment. Interestingly, 
AraC treatment induced cell cycle arrest in Necdin null 
leukemia cells expressing MLL-AF9 (Figure 3F). The 
cell cycle arrest may be due to increased expression of 
p53 in Necdin null cells following AraC treatment (Figure 
3G). Thus, Necdin deficiency may sensitize leukemia 
cells expressing MLL-AF9 to AraC treatment through 
decreasing LIC quiescence and inducing p53-dependent 
apoptosis and cell cycle arrest.
In contrary to the effect of Necdin deficiency on 
the response of leukemia cells expressing MLL-AF9 to 
AraC treatment, loss of Necdin did not affect the viability 
of leukemia cells expressing AML1-ETO9a following 
chemotherapy treatment (Figures 6A, 6B and 6C). While 
Necdin null leukemia cells expressing AML1-ETO9a show 
enhanced apoptosis at 48 hours after high concentration 
of AraC treatment (Figure 6E), these cells had decreased 
apoptosis at 72 hours after AraC treatment (Figure 6G). 
Given that Necdin null leukemia cells expressing either 
MLL-AF9 or AML1-ETO9a show enhanced apoptosis 
at 48 hours after AraC treatment (Figures 3E and 6E), 
it is likely that other mechanisms, including senescence, 
cell cycle arrest, and autophagy, may contribute to the 
differential response of leukemia cells expressing MLL-
AF9 or AML1-ETO9a to AraC treatment.
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The leukemia stem cells in AML1-ETO-induced 
leukemia are HSCs whereas LSCs in MLL-AF9-induced 
leukemia are GMPs [13, 46–47]. While Necdin is highly 
expressed in HSCs, the expression of Necdin in progenitor 
and mature cells is very low [28, 48]. The reason why 
Necdin plays very different roles in different types of 
leukemia may be due to Necdin levels are different between 
stem cells and progenitor cells. MLL-AF9 and AML1-
ETO regulates different gene expression signatures to 
drive leukemia development [12-13, and 47]. In addition, 
MLL-AF9 and AML1-ETO interact with distinct proteins 
in hematopoietic stem and progenitor cells [11-12, 19 and 
49]. Thus, it is likely that Necdin plays a context dependent 
role in modulating leukemia-initiating cell quiescence 
and chemo-sensitivity. The mechanisms by which Necdin 
modulates leukemia development in response to different 
oncogenes require further investigation.
In summary, we discovered that Necdin null LICs 
expressing MLL-AF9 are less quiescent than wild-type 
LICs and Necdin-deficiency enhanced the response of 
MLL-AF9+ leukemia cells to chemotherapy treatment. 
Given that human leukemia patients with MLL-AF9 are 
resistant to chemotherapy [1, 11], our findings suggest 
that pharmacological inhibition of Necdin may hold 




The generation of Necdin null mice (C57BL/6, 
CD45.2) was described previously [42]. Fetal liver cells were 
isolated from E14.5 embryos as previously described [21]. 
Wild type C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice 
were purchased from Jackson Laboratories. All mice were 
maintained in the Indiana University School of Medicine 
Animal Facility according to IACUC-approved protocols, 
and kept in Thorensten units with filtered germ-free air.
Transduce fetal liver cells with retrovirus
Retroviral particles were produced by transfection 
of Phoenix E cells with the MSCV-MLL-AF9- IRES-
GFP or MSCV-AML1-ETO9a-IRES-GFP plasmids, 
according to standard protocols [17]. Murine fetal liver 
cells were transduced on retronectin (Takara)-coated non-
tissue culture plates with high-titer retroviral suspensions. 
Seventy-two hours after infection, GFP-positive cells were 
sorted by FACS.
Flow cytometry
Flow cytometry analysis of hematopoietic stem and 
progenitor cells was performed as described previously 
[20–21]. Nuclear staining of Ki67 was done by using 
an FITC-anti-human Ki67 antibody (BD PharMingen) 
and fixation and permeabilization solutions from BD 
Biosciences [21]. Flow antibodies were purchased from 
Biolegend, eBioscience or BD Bioscience. Experiments 
were performed on FACSAria and FACSLSR II 
cytometers (BD Biosciences) and analyzed by using the 
FlowJo Version 9.3.3 software (TreeStar).
Stem and progenitor cell assays
Clonogenic progenitors were determined in 
methylcellulose medium (MethoCult GF M3434, 
StemCell Technologies) using 2 x 103 fetal liver cells per 
well (6-well plate) [20–21]. Colonies were scored after 7 
days of the initial culture, and all cells were collected and 
washed twice in phosphate-buffered saline. Subsequently 
cells were cultured at 2 x104 per well in the same medium. 
Colony scoring and replating were repeated every 7 days 
for at least four times, or until no colonies were observed 
in the cultures.
Transplantation assay
We transplanted 1 x 105 fetal liver cells from wild 
type and Necdin null mice (CD45.2+) that expressing 
MLL-AF9 or AML1-ETO9a into lethally irradiated 
B6.SJL mice (CD45.1+) together with 1 x 105 normal 
competitor cells (CD45.1+). The presence of GFP+ cells 
in the peripheral blood was measured by flow cytometry 
analysis every 4 weeks. 16 weeks following primary 
transplantation, we harvested bone marrow cells from 
mice reconstituted with wild type or Necdin null fetal 
liver cells and transplanted 3 x 106 bone marrow cells into 
lethally irradiated B6.SJL mice (CD45.1+).
Chemotherapy treatment
Leukemia cells expressing MLL-AF9 or AML1-
ETO9a we treated with DMSO or different concentrations 
of cytarabine (AraC) for 24 hours, 48 hours and 72 hours, 
respectively [50]. The proliferation of leukemia cells was 
determined by FACS analysis. The viability of leukemia 
cells following AraC treatment was evaluated by PI/
Annexin V staining. Early apoptotic cells were defined as 
Annexin V+ PI- cells and late apoptotic cells were defined 
as Annexin V+ PI+ cells.
Statistical analysis
The animal sample size was based on previous 
studies evaluating the roles of AML1-ETO9a in leukemia 
and POWER analysis [17]. Gehan-Breslow-Wilcoxon test 
was used for Kaplan-Meier survival curves. The other data 
were analyzed by paired or unpaired t test using GraphPad 
Prizm 6. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not 
significant. All experiments were repeated at least once.
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